CLDX FY 2024 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+2.0% YoY

Gross Profit

-$157M-2229.8% margin

Operating Income

-$195M-2778.9% margin

Net Income

-$158M-2248.8% margin

EPS (Diluted)

$-2.45

Cash Flow

Operating Cash Flow

-$158M

Free Cash Flow

-$160M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$792M

Total Liabilities

$45M

Stockholders' Equity

$747M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	+2.0%
Gross Profit	-$157M	-$111M	-40.9%
Operating Income	-$195M	-$155M	-26.2%
Net Income	-$158M	-$141M	-11.6%